Introduction
Novo Nordisk holds approximately one-third of the global branded diabetes treatment market and is a world-leading provider of diabetes care products. Headquartered in Denmark, the company manufactures and markets a wide range of human and modern insulins, injectable diabetes treatments such as GLP-1 therapies, oral antidiabetic medications, and obesity treatments. Novo Nordisk also has a biopharmaceutical division (contributing less than 10% of revenue) specializing in protein therapies for hemophilia and other diseases.
